Corporate | 28 July 2011 07:00
|
Cytos Biotechnology AG / Key word(s): Half Year Results
Cytos Biotechnology Ltd Second Quarter Report 2011 as of June 30, 2011 Summary of important events in Q2 2011 – Update on combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus – Phase IIb results with CYT003-QbG10 for the treatment of allergic rhinoconjunctivitis published in the Journal 'Clinical and Experimental Allergy' – Constitution of the Board of Directors after the Shareholder's Meeting 2011 – Financial summary
*YTD = year to date January 1 – June 30 The complete Second Quarter Report 2011 can be downloaded on Cytos Biotechnology's website under the following link: http://www.cytos.com/userfiles/file/Cytos_Q2_2011_E.pdf For more information please contact:
Harry Welten, MBA
End of Corporate News 28.07.2011 News transmitted by EquityStory AG. The issuer is responsible for the contents of the release. EquityStory publishes regulatory releases, media releases on the capital market and press releases. The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies. The Swiss news archive can be found at http://www.equitystory.ch/nachrichten |
| Language: | English | |
| Company: | Cytos Biotechnology AG | |
| Wagistr. 25 | ||
| 8952 Schlieren | ||
| Switzerland | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@cytos.com | |
| Internet: | www.cytos.com | |
| ISIN: | CH0011025217, CH0029060735 | |
| Swiss Security Number: | – | |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt | |
| End of News | EquityStory AG News-Service |
|
|
| 133436 28.07.2011 |